Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma

Hum Pathol. 2008 Feb;39(2):209-12. doi: 10.1016/j.humpath.2007.06.004. Epub 2007 Oct 18.

Abstract

Glypican 3 is an oncofetal antigen that shows great promise as an adjunct to the diagnosis of hepatocellular carcinoma. To investigate whether glypican 3 might also appear in nonneoplastic liver cells, we performed immunostains on 60 biopsies of chronic hepatitis C, 30 with low-grade activity and 30 with high-grade activity. Glypican 3 immunoreactivity was detected in 25 (83.6%) of 30 in the high-grade but in none in the low-grade group. In 20% of the positive cases, glypican 3 produced strong cytoplasmic staining of more than 25% of hepatocytes and could potentially lead to a misdiagnosis of hepatocellular carcinoma. Pathologists should be aware of this phenomenon and exercise caution in interpreting biopsies or other specimens of suspected hepatocellular carcinoma when active necroinflammatory disease is present.

MeSH terms

  • Biomarkers / metabolism*
  • Biopsy
  • Carcinoma, Hepatocellular / diagnosis*
  • Cytoplasm / metabolism
  • Cytoplasm / pathology
  • Diagnosis, Differential
  • Glypicans / metabolism*
  • Hepatitis C, Chronic / metabolism*
  • Hepatocytes / metabolism
  • Hepatocytes / pathology
  • Humans
  • Ki-67 Antigen / metabolism
  • Liver Neoplasms / diagnosis*

Substances

  • Biomarkers
  • Glypicans
  • Ki-67 Antigen